100 related articles for article (PubMed ID: 26186064)
1. The antileukemia effect of metformin in the Philadelphia chromosome-positive leukemia cell line and patient primary leukemia cell.
Shi R; Lin J; Gong Y; Yan T; Shi F; Yang X; Liu X; Naren D
Anticancer Drugs; 2015 Oct; 26(9):913-22. PubMed ID: 26186064
[TBL] [Abstract][Full Text] [Related]
2. Ribavirin Inhibits the Activity of mTOR/eIF4E, ERK/Mnk1/eIF4E Signaling Pathway and Synergizes with Tyrosine Kinase Inhibitor Imatinib to Impair Bcr-Abl Mediated Proliferation and Apoptosis in Ph+ Leukemia.
Shi F; Len Y; Gong Y; Shi R; Yang X; Naren D; Yan T
PLoS One; 2015; 10(8):e0136746. PubMed ID: 26317515
[TBL] [Abstract][Full Text] [Related]
3. [Multidrug resistant gene MDR1 contributes to development of imatinib-resistance in Ph (+) acute lymphoblastic leukemia cell line SUP-BS15RI].
Lin J; Xing HY; Gong YP; Yang X; Guo Y; Shan QQ; Zhou RQ
Sichuan Da Xue Xue Bao Yi Xue Ban; 2012 Sep; 43(5):657-60, 665. PubMed ID: 23230732
[TBL] [Abstract][Full Text] [Related]
4. [The anti-leukemic effects of imatinib, daunorubicin and bortezomib on two leukemia cell lines with Ph(+)].
Yang X; Yang L; Gong YP; Chang H; Zhou RQ; Xing HY; Zheng BH
Sichuan Da Xue Xue Bao Yi Xue Ban; 2010 Sep; 41(5):793-6. PubMed ID: 21302443
[TBL] [Abstract][Full Text] [Related]
5. Mammalian target of rapamycin inhibitor rapamycin enhances anti-leukemia effect of imatinib on Ph+ acute lymphoblastic leukemia cells.
Yang X; He G; Gong Y; Zheng B; Shi F; Shi R; Yang X
Eur J Haematol; 2014 Feb; 92(2):111-20. PubMed ID: 24112092
[TBL] [Abstract][Full Text] [Related]
6. [Effect of VE-cadherin on sensitivity to Imatinib in Sup-B15 Philadelphia chromosome positive acute lymphoblastic leukemia cells].
Zhang HX; Yan ZL; Song XG; Lü C; Cao J; Li ZY; Zeng LY; Chen C; Xu KL
Zhonghua Xue Ye Xue Za Zhi; 2013 Jun; 34(6):522-6. PubMed ID: 23827112
[TBL] [Abstract][Full Text] [Related]
7. The study of resistant mechanisms and reversal in an imatinib resistant Ph+ acute lymphoblastic leukemia cell line.
Xing H; Yang X; Liu T; Lin J; Chen X; Gong Y
Leuk Res; 2012 Apr; 36(4):509-13. PubMed ID: 22285507
[TBL] [Abstract][Full Text] [Related]
8. Methyl-β-cyclodextrin induces programmed cell death in chronic myeloid leukemia cells and, combined with imatinib, produces a synergistic downregulation of ERK/SPK1 signaling.
Yan J; Li QF; Wang LS; Wang H; Xiao FJ; Yang YF; Wu CT
Anticancer Drugs; 2012 Jan; 23(1):22-31. PubMed ID: 21857502
[TBL] [Abstract][Full Text] [Related]
9. Anti-leukemic activity of valproic acid and imatinib mesylate on human Ph+ ALL and CML cells in vitro.
Kircher B; Schumacher P; Petzer A; Hoflehner E; Haun M; Wolf AM; Nachbaur D; Gastl G
Eur J Haematol; 2009 Jul; 83(1):48-56. PubMed ID: 19226363
[TBL] [Abstract][Full Text] [Related]
10. Stromal cells attenuate the cytotoxicity of imatinib on Philadelphia chromosome-positive leukemia cells by up-regulating the VE-cadherin/β-catenin signal.
Chen C; Zhang HX; Wang M; Song XG; Cao J; Wang L; Qiao JL; Lu XY; Han ZX; Zhu P; Pan B; Wu QY; Zhao K; Yan ZL; Li ZY; Zeng LY; Xu KL
Leuk Res; 2014 Dec; 38(12):1460-8. PubMed ID: 25443888
[TBL] [Abstract][Full Text] [Related]
11. Divalproex sodium enhances the anti-leukemic effects of imatinib in chronic myeloid leukemia cells partly through SIRT1.
Wang W; Zhang J; Li Y; Yang X; He Y; Li T; Ren F; Zhang J; Lin R
Cancer Lett; 2015 Jan; 356(2 Pt B):791-9. PubMed ID: 25449787
[TBL] [Abstract][Full Text] [Related]
12. The autophagy induced by curcumin via MEK/ERK pathway plays an early anti-leukemia role in human Philadelphia chromosome-positive acute lymphoblastic leukemia SUP-B15 cells.
Guo Y; Shan QQ; Gong PY; Wang SC
J Cancer Res Ther; 2018; 14(Supplement):S125-S131. PubMed ID: 29578162
[TBL] [Abstract][Full Text] [Related]
13. Synergistic killing effect of imatinib and simvastatin on imatinib-resistant chronic myelogenous leukemia cells.
Oh B; Kim TY; Min HJ; Kim M; Kang MS; Huh JY; Kim Y; Lee DS
Anticancer Drugs; 2013 Jan; 24(1):20-31. PubMed ID: 23075630
[TBL] [Abstract][Full Text] [Related]
14. CD19-targeting liposomes containing imatinib efficiently kill Philadelphia chromosome-positive acute lymphoblastic leukemia cells.
Harata M; Soda Y; Tani K; Ooi J; Takizawa T; Chen M; Bai Y; Izawa K; Kobayashi S; Tomonari A; Nagamura F; Takahashi S; Uchimaru K; Iseki T; Tsuji T; Takahashi TA; Sugita K; Nakazawa S; Tojo A; Maruyama K; Asano S
Blood; 2004 Sep; 104(5):1442-9. PubMed ID: 15155467
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological agents with inherent anti-autophagic activity improve the cytotoxicity of imatinib.
Crowley LC; O'Donovan TR; Nyhan MJ; McKenna SL
Oncol Rep; 2013 Jun; 29(6):2261-8. PubMed ID: 23564048
[TBL] [Abstract][Full Text] [Related]
16. CUEDC2 sensitizes chronic myeloid leukemic cells to imatinib treatment.
Zhang H; Chang G; Wang J; Lin Y; Ma L; Pang T
Leuk Res; 2013 Nov; 37(11):1583-91. PubMed ID: 24125838
[TBL] [Abstract][Full Text] [Related]
17. Persistent activation of the Fyn/ERK kinase signaling axis mediates imatinib resistance in chronic myelogenous leukemia cells through upregulation of intracellular SPARC.
Fenouille N; Puissant A; Dufies M; Robert G; Jacquel A; Ohanna M; Deckert M; Pasquet JM; Mahon FX; Cassuto JP; Raynaud S; Tartare-Deckert S; Auberger P
Cancer Res; 2010 Dec; 70(23):9659-70. PubMed ID: 21098700
[TBL] [Abstract][Full Text] [Related]
18. Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate.
Nguyen TK; Rahmani M; Gao N; Kramer L; Corbin AS; Druker BJ; Dent P; Grant S
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2239-47. PubMed ID: 16609040
[TBL] [Abstract][Full Text] [Related]
19. Drug responses of imatinib mesylate-resistant cells: synergism of imatinib with other chemotherapeutic drugs.
Tipping AJ; Mahon FX; Zafirides G; Lagarde V; Goldman JM; Melo JV
Leukemia; 2002 Dec; 16(12):2349-57. PubMed ID: 12454739
[TBL] [Abstract][Full Text] [Related]
20. Bone marrow microenvironment confers imatinib resistance to chronic myelogenous leukemia and oroxylin A reverses the resistance by suppressing Stat3 pathway.
Li X; Miao H; Zhang Y; Li W; Li Z; Zhou Y; Zhao L; Guo Q
Arch Toxicol; 2015 Jan; 89(1):121-36. PubMed ID: 24671465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
